Aims: To simplify administration of aqueous exenatide once weekly, which requires reconstitution, the exenatide microspheres have been reformulated in a ready-to-use autoinjector with a Miglyol diluent (exenatide QWS-AI). This study compared the efficacy and safety of exenatide QWS-AI with the first-in-class glucagon-like peptide-1 receptor agonist exenatide twice daily (BID).
| INTRODUCTION
Patients with type 2 diabetes require long-term treatment to achieve and maintain glycaemic control; thus, the availability of therapeutic options that are effective and simple to administer is important. The initial formulation of exenatide, a first-in-class glucagon-like peptide-1 receptor agonist (GLP-1RA) that has been used clinically for over 10 years, is still available but requires twice-daily (BID) subcutaneous administration (exenatide BID). Subsequently, exenatide was packaged into biodegradable poly-(D,L-lactide-co-glycolide) microspheres that allow for once-weekly (QW) administration but require reconstitution in an aqueous diluent before injection. A single dose of exenatide QW results in the gradual release of exenatide from the microspheres over approximately 10 weeks. 1 When administered every 7 days, the therapeutic threshold is reached after 2 weeks, and steady-state plasma concentrations are achieved after approximately 7 weeks. 2 Patients receiving exenatide QW over time have demonstrated sustained reductions from baseline in glycated haemoglobin (HbA1c) and body weight. 3, 4 To improve ease of use, development efforts were directed at simplifying the delivery of exenatide-containing microspheres by eliminating the need for reconstitution in aqueous diluent before administration. Exenatide QW suspension by autoinjector (exenatide QWS This study compared the efficacy, safety and tolerability of exenatide QWS-AI with the original exenatide BID formulation over 28 weeks of treatment in patients with type 2 diabetes. ]) at screening. They were randomized in a 3:2 ratio to treatment with exenatide QWS-AI or exenatide BID, respectively. Randomization was done centrally through an interactive web system by studysite personnel.
| MATERIALS AND METHODS

| Patients and study design
Upon randomization, patients received injections of either exenatide QWS-AI (2 mg) with a 23-gauge needle 1 or exenatide BID (5 μg for 4 weeks, 10 μg subsequently; administered 60 minutes before morning and evening meals) with a 29-to 31-gauge needle. 5 Prior concomitant glucose-lowering medications were continued at pretrial doses, and patients continued prescribed diet and exercise regimens. A subset of patients from select study sites also participated in a standardized meal test to assess postprandial glycaemic and pharmacokinetic measures. Meal test assessments were completed at baseline and at 16 weeks.
The study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board for each study site. All patients provided written informed consent.
| End points and assessments
The primary efficacy end point for the study was change in HbA1c 
| Statistical methods
The target sample size was approximately 375 patients, with an anticipated withdrawal rate of 15% by week 28. A sample size of 225 patients randomized to receive exenatide QWS-AI and 150 patients randomized to receive exenatide BID was estimated to
provide >95% power to demonstrate that exenatide QWS-AI is noninferior to exenatide BID (within a 0.4% noninferiority upper margin)
in the HbA1c change from baseline to week 28, assuming a common standard deviation (SD) of 1.15% and an expected mean difference of −0.1% or less (exenatide QWS-AI − exenatide BID).
The sample size was estimated to provide 91% power to show superiority of exenatide QWS-AI in HbA1c change from baseline to week 28, assuming a common SD of 1.15% and a mean difference of
The modified intention-to-treat (mITT) population, which comprised all randomized patients who received at least 1 dose of study drug, was used for efficacy and pharmacodynamic analyses. A full description of the study populations used for analysis is available online in Appendix S1.
Efficacy measures were summarized descriptively by treatment, and comparisons were made using the mixed-effects model for Change-from-baseline data are presented as the least-squares mean and standard error of the least-squares mean, and the difference in change between groups is reported as the least-squares mean difference and standard error of the least-squares mean difference, unless otherwise noted. A closed testing procedure was implemented to preserve the family-wise type I error rate; noninferiority was evaluated first, and if achieved, superiority for the primary end point was assessed. For the primary end point, a 2-sided significance level of 0.05 was used. Missing data were imputed using the last-observation-carried-forward method.
Incremental area under the curve was calculated to assess the postprandial response as a baseline-subtracted measure of area under the curve for glucose, serum insulin and triglyceride measures.
3 | RESULTS
| Patients
The study, including the extension phase, was conducted from Certain patient demographic characteristics were tested for interaction with the treatment difference between exenatide QWS-AI and exenatide BID. No treatment interaction was found for age or sex, but a significant treatment interaction was found for race (treatmentby-week-by-race, P = .0007). HbA1c was reduced by −1.5% and nominal P = .0999). exenatide QWS-AI compared with exenatide BID after 16 weeks of treatment (Table S1 , Appendix S1). Postprandial serum triglycerides decreased after 16 weeks with both exenatide QWS-AI and exenatide BID, with a greater decrease in postprandial lipaemia with exenatide BID (Table S1 , Appendix S1).
| Additional efficacy end points
| Efficacy with sulfonylurea use
The use of sulfonylurea (exenatide QWS-AI, n = 89; exenatide BID, n = 60) vs no use of sulfonylurea (exenatide QWS-AI, n = 140; exenatide BID, n = 86) was associated with a lesser reduction in HbA1c, FPG and body weight for both treatments ( Figure S1 , Appendix S1). A 
| Cardiovascular risk factors
Several cardiovascular risk factors were evaluated after 28 weeks (Table S2 , Appendix S1). Both exenatide QWS-AI (−0.8 AE 1.1 mm Hg) and exenatide BID (−1.6 AE 1.4 mm Hg) recipients had reductions in systolic BP (difference, 0.8 AE 1.6 mm Hg; nominal P = .61). Diastolic BP increased slightly with exenatide QWS-AI and decreased with exenatide BID (difference, 2.0 AE 0.9 mm Hg; nominal P = .03). Heart rate increased slightly in both groups (mean AE SD: exenatide QWS-AI, 1.9 AE 9.4 beats/min; exenatide BID, 1.6 AE 8.5 beats/min). There were no clinically meaningful changes in fasting lipids or other cardiovascular risk factors, including high-sensitivity C-reactive protein, brain natriuretic peptide or urinary albumin/creatinine ratio (data not shown).
| Safety and tolerability results
The most common AEs were gastrointestinal in nature (Table 2) and occurred more often with exenatide BID than with exenatide QWS-AI.
The proportion of patients with gastrointestinal AEs was lower with exenatide QWS-AI (n = 52/229; 22.7%) than with exenatide BID The majority of these patients displayed low titers, and antibody status had no observable impact on the change in HbA1c over 28 weeks (Table S3 , Appendix S1).
| Pharmacokinetics
The AEs, most commonly nausea and vomiting, appeared less frequently with exenatide QW or liraglutide than with exenatide BID. 16 Diarrhea occurred at a similar frequency. The improved tolerability of the longacting formulations of exenatide may be related to the gradual increase in plasma concentration from the microspheres, which provides a natural titration process. 2 However, the microsphere formulation contributed to the increased frequency of injection-site reactions reported in the current study with exenatide QWS-AI compared with exenatide BID, because the drug being administered was the same.
The DURATION-1 9 and DURATION-5 10 studies also found injectionsite reactions to occur more frequently with exenatide QW than with exenatide BID.
In addition to increasing the incidence of hypoglycaemia, the current study found concomitant sulfonylurea use to be associated with reduced efficacy, of both exenatide QWS-AI and exenatide BID. The EUREXA study, which compared exenatide BID with glimepiride (a sulfonylurea), found that treatment failure was less common with exenatide BID than with glimepiride (41% with exenatide BID, 54% with glimepiride; P = .002). 17 HbA1c was also reduced significantly more with exenatide BID treatment than with a sulfonylurea. It is possible that sulfonylurea use in combination with a GLP-1RA, as well as in monotherapy, negatively affects treatment response over time.
Alternatively, patients taking a sulfonylurea may have more advanced type 2 diabetes than patients undergoing monotherapy, or may experience a more rapid decline in beta-cell function. 18 This study has limitations. The open-label design may have contributed to bias in the study conduct and patient behaviors. Proportionately, more patients withdrew from the exenatide BID group. In addition, the sample size was too small for conclusions to be made on potential interactions between demographic characteristics and response to therapy, and the imbalance in the randomization ratio may have affected the power for primary and secondary end points.
Diet and exercise behaviors were not recorded.
Overall, this study found that both the new formulation (exenatide QWS-AI) and exenatide BID improved glycaemic control and reduced body weight in patients with type 2 diabetes. However, treatment with exenatide QWS-AI resulted in a greater improvement in HbA1c.
Although not statistically significant, there was a greater reduction in FPG with exenatide QWS-AI and a greater reduction in 2-hour PPG with exenatide BID. This pattern of efficacy is characteristic for a longacting GLP-1RA. Additionally, exenatide QWS-AI was associated with an improved AE profile and fewer treatment discontinuations than was exenatide BID.
